In addition, our results could be supported by the opinion of Rodragguez-Iturbe et al. who mentioned that current available PDE-5 inhibitors have potential clinical value in the treatment of chronic renal disease [54]. The gene discussed is PDE5A; the disease is chronic kidney disease.